ClinicalTrials.gg
Not yet recruitingNCT06757335Updated Jan 3, 2025

A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

A Phase 1/2 interventional study of HP568 and HP568 in combination with palbociclib in Breast Cancer, sponsored by Hinova Pharmaceuticals Inc.. Not yet recruiting. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by Hinova Pharmaceuticals Inc. · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
204
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.

Planned enrollment
29th of 111
204 · median 100
Started
2025
with 6 others
Phase 1/2
5 of 111
none open now
Primary completion
2026-01
later than 18 of 42 live
Registered
102nd of 111
by date

Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 29th largest by planned enrollment, is one of 7 that started in 2025, is one of 5 in phase 1/2, reaches primary completion later than 18 of the 42 other live ones, and was the 102nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About palbociclib

palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing palbociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or metastatic breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged 18-75 years old (inclusive of both ends) at the time of signing the form.
  2. Patients with locally advanced inoperable or recurrent or breast cancer ER+/- advanced breast cancer is confirmed by histopathology have confirmed that the primary and/or metastatic lesion.
  3. Previously received at least 1-line endocrine therapy (endocrine therapy duration ≥ 6 months) and ≤ 2-line chemotherapy (≤ 2-line chemotherapy limited to dose escalation stage) for the recurrence or metastasis stage of the disease. The third stage : Inclusion of patients who have not received prior treatment but are suitable for CDK4/6i therapy.
  4. Disease progression confirmed by imaging occurs during or after the last systemic anti-tumor treatment before the first medication.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to any ingredient of HP568 formulation, and allergy to any ingredient of palbociclib (only applicable to stage III).
  2. Within 42 days prior to the first administration, Fluvistran was used; Other endocrine therapies such as tamoxifen, toremifene, letrozole, anastrozole, and exemestane were used within 14 days prior to the first administration.
  3. Previously received other ER-ROTAC drugs such as ARV-471.
  4. Within 6 weeks before the first administration of HP568 in this study, nitrosoureas or mitomycin were used; Received any anti-tumor treatment, including immunotherapy, chemotherapy, radiotherapy, or targeted therapy, within 28 days prior to the first administration (or of the drug's 5 half lives,take the shorter one).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    HP568

    In the I/II stage: HP568 administered QD or BID for 28 day cycles.

    Drug: HP568

  • Experimental
    HP568 and palbociclib

    In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.

    Drug: HP568 in combination with palbociclib

Interventions

  • DrugHP568

    In the I/II stage: HP568 administered QD or BID for 28 day cycles.

  • DrugHP568 in combination with palbociclib

    Drug page: PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.

06

What researchers measure

Primary outcomes

  1. Stage I: the incidence of TEAE of HP568

    the percentage of patients with treatment-emergent Adverse events(TEAE), TEAE will be evaluated using CTCAE 5.0 standards.

    Time frame: From the first administration dose to 30 calendar days after the last administration dose

  2. Stage I: Incidence of dose limiting toxicity DLT, maximum tolerated dose MTD (if possible).

    First cycle dose-limiting toxicities and determination of a maximum tolerated dose (MTD) if applicable among the doses evaluated

    Time frame: 28 days

  3. Stage III: Evaluate safety during the dose escalation phase of combination therapy

    Adverse events will be evaluated using the CTCAE5.0 standard, and safety features will be based on the assessment of adverse events, including TEAE, laboratory indicators (blood routine, blood biochemistry, coagulation routine, blood lipids, urine routine), vital sign measurements (blood pressure, pulse, respiratory rate, and body temperature), physical examination, and 12 lead electrocardiogram.

    Time frame: From the first administration dose to 30 calendar days after the last administration dose

  4. Stage III: Evaluate tolerance during the dose escalation phase of combination therapy

    First cycle dose-limiting toxicities and determination of a maximum tolerated dose (MTD) if applicable among the doses evaluated

    Time frame: 28 days

  5. Stage III: Evaluate the 24 week clinical benefit rate (CBR) during the dose escalation phase of combination therapy

    According to RECIST 1.1 criteria, the proportion of subjects who achieve confirmed CR (complete response) and/or confirmed PR (partial response) within 24 weeks plus at least 24 weeks of SD (stable disease).

    Time frame: Until all patients have completed 24 weeks administration

  6. Stage II: 24 week clinical benefit rate (CBR)

    According to RECIST 1.1 criteria, the proportion of subjects who achieve confirmed CR (complete response) and/or confirmed PR (partial response) within 24 weeks plus at least 24 weeks of SD (stable disease).

    Time frame: Until all patients have completed 24 weeks administration

Secondary outcomes

  1. Stage I-III: Objective response rate (ORR)

    According to RECIST 1.1 criteria, the proportion of subjects who achieve CR (complete response)+PR (partial response).

    Time frame: Until all patients have completed study(approximately 2 years)

  2. Stage I/III: 24 week clinical benefit rate (CBR)

    According to RECIST 1.1 criteria, the proportion of subjects who achieve confirmed complete response (CR) and/or confirmed partial response (PR) within 24 weeks plus at least 24 weeks of stable disease (SD).

    Time frame: Until all patients have completed 24 weeks administration

  3. Stage I-III: Disease Control Rate (DCR)

    The proportion of subjects who achieve response and disease stability (i.e. CR+PR+SD) after treatment.

    Time frame: Until all patients have completed study(approximately 2 years)

  4. Stage I-III: Progression free survival (PFS)

    from the start of treatment until tumor progression or death from any cause, which comes first.

    Time frame: Until all patients have completed study(approximately 2 years)

  5. Stage I-III: Duration of response(DOR)

    the time from the first onset of response (CR or PR) to disease progression

    Time frame: Until all patients have completed study(approximately 2 years)

  6. Stage I-III: Time to Response (TTR)

    The time from the start of treatment to the first recorded achievement of response (CR or PR).

    Time frame: Until all patients have completed study(approximately 2 years)

  7. Stage I-II:Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC)

    Concentration-time curve (AUC) for single and multiple dose of HP568 will be assessed after a single dose and after multiple doses.

    Time frame: on the first day of cycle 1 and cycle 2(each cycle is 28 days)

  8. Stage I-II:Assessment of pharmacokinetic parameter maximum concentration (Cmax)

    Maximum concentration (Cmax) for single and multiple dose of HP568 will be assessed after a single dose and after multiple doses.

    Time frame: on the first day of cycle 1 and cycle 2(each cycle is 28 days)

  9. Stage I-II: Assessment of pharmacokinetic parameter minimum concentration (Cmin).

    minimum concentration (Cmin) for single and multiple dose of HP568 will be assessed after a single dose and after multiple doses.

    Time frame: on the first day of cycle 1 and cycle 2 (each cycle is 28 days)

  10. Stage I-II:Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax) for HP568 will be assessed after a single dose and after multiple doses.

    Time frame: on the first day of cycle 1 and cycle 2 (each cycle is 28 days)

  11. Stage III:Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC)

    Concentration-time curve (AUC) of HP568 and palbociclib will be assessed after single and multiple doses.

    Time frame: on the Day 1 and Day 21 of cycle 1 (each cycle is 28 days)

  12. Stage III: Assessment of pharmacokinetic parameter maximum concentration (Cmax)

    maximum concentration (Cmax) of HP568 and palbociclib will be assessed after a single dose and after multiple doses

    Time frame: on the Day 1 and Day 21 of cycle 1 (each cycle is 28 days)

  13. Stage III: Assessment of pharmacokinetic parameter minimum concentration (Cmin)

    Minimum concentration (Cmin) of HP568 and palbociclib will be assessed after a single dose and after multiple doses.

    Time frame: on the Day 1 and Day 21 of cycle 1 (each cycle is 28 days)

  14. Stage III: Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax) of HP568 and palbociclib will be assessed after a single dose and after multiple doses.

    Time frame: on the Day 1 and Day 21 of cycle 1 (each cycle is 28 days)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Jan 2026, 12 months later.

Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 12 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Jan 3, 2025
StartEst.
Jan 7, 2025
Primary completionEst.
Jan 31, 2026
CompletionEst.
Nov 27, 2026
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06757335
Lead sponsor
Hinova Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Jan 3, 2025
Start date
Jan 7, 2025 (estimated)
Primary completion
Jan 31, 2026 (estimated)
Completion
Nov 27, 2026 (estimated)
Last update
Jan 3, 2025

Study contacts

Zhonghua Zhou
Contact
zhzhou1@hinovapharma.com
+86-28-85058465

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion